The brain disease device and software market size has grown rapidly in recent years. It will grow from $15.59 billion in 2025 to $17.2 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to limited availability of brain disease diagnostic tools, growing prevalence of neurological disorders, rising hospital and clinic infrastructure, early-stage adoption of telemedicine solutions, dependence on traditional brain imaging techniques.
The brain disease device and software market size is expected to see rapid growth in the next few years. It will grow to $25.21 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to advancements in wearable and ai-enabled brain disease devices, increased investment in neurorehabilitation technologies, expansion of home care and remote monitoring solutions, rising demand for brain data management software, growing research in neuroinformatics and cognitive assessment technologies. Major trends in the forecast period include rising adoption of neurostimulation and brain monitoring devices, integration of telemedicine and remote patient monitoring, growth in cognitive assessment and neurofeedback software, increasing focus on personalized brain disorder treatment, expansion of neuroimaging and data analytics solutions.
The rising prevalence of neurological disorders is expected to drive growth in the brain disease device and software market. Neurological disorders affect the brain, spinal cord, and nerves, causing cognitive, motor, and sensory impairments. Their increasing occurrence is associated with the aging global population, as aging reduces neuronal function, decreases brain plasticity, and increases oxidative stress, contributing to disease onset and progression. Brain disease devices and software aid in managing these conditions by enabling early diagnosis and continuous monitoring. Advanced AI and data analytics support timely intervention, improving patient care and treatment outcomes. For example, in July 2024, the UK’s National Health Service reported 487,432 patients diagnosed with dementia by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. Consequently, the growing prevalence of neurological disorders is fueling the brain disease device and software market.
Major companies operating in the brain disease device and software market are increasingly concentrating on the adoption of advanced technologies, such as artificial intelligence (AI)-enabled brain imaging analytics, to improve the early and precise detection, monitoring, and management of neurodegenerative disorders including Alzheimer’s disease and dementia. Artificial intelligence-driven brain imaging analytics refers to sophisticated software platforms that utilize machine-learning algorithms on MRI and other neuroimaging datasets to detect subtle microstructural changes in brain tissue that may not be captured by conventional volumetric imaging, thereby facilitating earlier and more sensitive diagnosis. For example, in January 2025, Oxford Brain Diagnostics Ltd., a UK-based medtech company, obtained U.S. Food and Drug Administration (FDA) 510(k) clearance and subsequently launched CDM Insights, a cloud-native software solution built on its proprietary Cortical Disarray Measurement (CDM) technology. The solution evaluates standard 1.5 T and 3 T MRI scans to produce novel metrics of cortical thickness and microstructural disarray in grey matter, delivering objective and quantifiable markers of neurodegeneration. Following regulatory clearances, the company commenced commercial deployment across healthcare systems in the US and UK, assisting clinicians with early diagnosis, disease monitoring, and treatment stratification.
In January 2025, NVIDIA entered into a partnership with Synchron Inc. to advance implantable brain-computer interface (BCI) technology through the use of NVIDIA’s Holoscan platform, enabling real-time neural processing and scalable brain-language models. Through this collaboration, NVIDIA Corporation seeks to integrate Synchron’s brain-computer interface platforms to enhance AI-driven neural signal processing and real-time analytics, thereby accelerating innovation in next-generation BCI applications. Synchron Inc., a US-based healthcare technology company, specializes in the development of minimally invasive brain-computer interface devices that facilitate neural signal acquisition and interaction for clinical and research applications.
Major companies operating in the brain disease device and software market are Medtronic plc, Insightec Ltd., Cadwell Industries Inc., NeuroPace Inc., Synchron Inc., Compumedics Ltd., Neuronetics Inc., BrainsWay Ltd., The Magstim Company Ltd., Paradromics Inc., Linus Health Inc., MagVenture A/S, Neurophet Inc., Neuroelectrics Corporation, BrainScope Company Inc, Blackrock Neurotech LLC, Neurable Inc., NeuroSigma Inc., Cognixion Inc., Brightmind.AI.
North America was the largest region in the brain disease device and software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain disease device and software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain disease device and software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the brain disease device and software market by increasing costs of imported high-tech equipment such as neuroimaging systems, wearable devices, and AI-enabled software platforms. Segments like neurostimulation devices and advanced brain imaging tools are most impacted, particularly in regions like North America and Asia-Pacific, where imports constitute a major share of supply. This has led to higher production costs and slowed adoption in some clinical and research settings. Positively, tariffs are encouraging local manufacturing, development of cost-effective alternatives, and innovation in domestic brain health solutions.
The brain disease device and software market research report is one of a series of new reports that provides brain disease device and software market statistics, including brain disease device and software industry global market size, regional shares, competitors with a brain disease device and software market share, detailed brain disease device and software market segments, market trends and opportunities, and any further data you may need to thrive in the brain disease device and software industry. This brain disease device and software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Brain disease devices and software refer to specialized medical tools and digital applications designed to diagnose, monitor, and manage neurological disorders and brain-related conditions. These solutions assist in detecting abnormalities, guiding therapies, and managing diseases, with the primary goal of improving patient outcomes through accurate assessment, personalized treatment, and continuous brain health monitoring.
The main categories of brain disease devices and software are brain disease devices and brain disease software. Brain disease devices are medical tools developed to diagnose, monitor, treat, or support rehabilitation for neurological disorders affecting brain function. They leverage technologies such as wearable devices, telemedicine platforms, artificial intelligence and machine learning, mobile health applications, and neuroimaging techniques. These devices are applied in conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and other neurological disorders, serving end users including hospitals and clinics, home care settings, rehabilitation centers, research and academic institutions, and diagnostic laboratories.
The brain disease device and software market consists of revenues earned by entities by providing services such as brain mapping services, remote neurological consultation, neurocognitive assessment, neurofeedback therapy, and personalised rehabilitation planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The brain disease devices and software market also includes sales of brain-computer interface systems, intracranial pressure monitors, transcranial magnetic stimulation devices, virtual reality-based rehabilitation kits, and portable electroencephalography headsets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The brain disease device and software market size is expected to see rapid growth in the next few years. It will grow to $25.21 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to advancements in wearable and ai-enabled brain disease devices, increased investment in neurorehabilitation technologies, expansion of home care and remote monitoring solutions, rising demand for brain data management software, growing research in neuroinformatics and cognitive assessment technologies. Major trends in the forecast period include rising adoption of neurostimulation and brain monitoring devices, integration of telemedicine and remote patient monitoring, growth in cognitive assessment and neurofeedback software, increasing focus on personalized brain disorder treatment, expansion of neuroimaging and data analytics solutions.
The rising prevalence of neurological disorders is expected to drive growth in the brain disease device and software market. Neurological disorders affect the brain, spinal cord, and nerves, causing cognitive, motor, and sensory impairments. Their increasing occurrence is associated with the aging global population, as aging reduces neuronal function, decreases brain plasticity, and increases oxidative stress, contributing to disease onset and progression. Brain disease devices and software aid in managing these conditions by enabling early diagnosis and continuous monitoring. Advanced AI and data analytics support timely intervention, improving patient care and treatment outcomes. For example, in July 2024, the UK’s National Health Service reported 487,432 patients diagnosed with dementia by June 30, 2024, an increase of 3,155 cases compared to May 31, 2024. Consequently, the growing prevalence of neurological disorders is fueling the brain disease device and software market.
Major companies operating in the brain disease device and software market are increasingly concentrating on the adoption of advanced technologies, such as artificial intelligence (AI)-enabled brain imaging analytics, to improve the early and precise detection, monitoring, and management of neurodegenerative disorders including Alzheimer’s disease and dementia. Artificial intelligence-driven brain imaging analytics refers to sophisticated software platforms that utilize machine-learning algorithms on MRI and other neuroimaging datasets to detect subtle microstructural changes in brain tissue that may not be captured by conventional volumetric imaging, thereby facilitating earlier and more sensitive diagnosis. For example, in January 2025, Oxford Brain Diagnostics Ltd., a UK-based medtech company, obtained U.S. Food and Drug Administration (FDA) 510(k) clearance and subsequently launched CDM Insights, a cloud-native software solution built on its proprietary Cortical Disarray Measurement (CDM) technology. The solution evaluates standard 1.5 T and 3 T MRI scans to produce novel metrics of cortical thickness and microstructural disarray in grey matter, delivering objective and quantifiable markers of neurodegeneration. Following regulatory clearances, the company commenced commercial deployment across healthcare systems in the US and UK, assisting clinicians with early diagnosis, disease monitoring, and treatment stratification.
In January 2025, NVIDIA entered into a partnership with Synchron Inc. to advance implantable brain-computer interface (BCI) technology through the use of NVIDIA’s Holoscan platform, enabling real-time neural processing and scalable brain-language models. Through this collaboration, NVIDIA Corporation seeks to integrate Synchron’s brain-computer interface platforms to enhance AI-driven neural signal processing and real-time analytics, thereby accelerating innovation in next-generation BCI applications. Synchron Inc., a US-based healthcare technology company, specializes in the development of minimally invasive brain-computer interface devices that facilitate neural signal acquisition and interaction for clinical and research applications.
Major companies operating in the brain disease device and software market are Medtronic plc, Insightec Ltd., Cadwell Industries Inc., NeuroPace Inc., Synchron Inc., Compumedics Ltd., Neuronetics Inc., BrainsWay Ltd., The Magstim Company Ltd., Paradromics Inc., Linus Health Inc., MagVenture A/S, Neurophet Inc., Neuroelectrics Corporation, BrainScope Company Inc, Blackrock Neurotech LLC, Neurable Inc., NeuroSigma Inc., Cognixion Inc., Brightmind.AI.
North America was the largest region in the brain disease device and software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain disease device and software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain disease device and software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the brain disease device and software market by increasing costs of imported high-tech equipment such as neuroimaging systems, wearable devices, and AI-enabled software platforms. Segments like neurostimulation devices and advanced brain imaging tools are most impacted, particularly in regions like North America and Asia-Pacific, where imports constitute a major share of supply. This has led to higher production costs and slowed adoption in some clinical and research settings. Positively, tariffs are encouraging local manufacturing, development of cost-effective alternatives, and innovation in domestic brain health solutions.
The brain disease device and software market research report is one of a series of new reports that provides brain disease device and software market statistics, including brain disease device and software industry global market size, regional shares, competitors with a brain disease device and software market share, detailed brain disease device and software market segments, market trends and opportunities, and any further data you may need to thrive in the brain disease device and software industry. This brain disease device and software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Brain disease devices and software refer to specialized medical tools and digital applications designed to diagnose, monitor, and manage neurological disorders and brain-related conditions. These solutions assist in detecting abnormalities, guiding therapies, and managing diseases, with the primary goal of improving patient outcomes through accurate assessment, personalized treatment, and continuous brain health monitoring.
The main categories of brain disease devices and software are brain disease devices and brain disease software. Brain disease devices are medical tools developed to diagnose, monitor, treat, or support rehabilitation for neurological disorders affecting brain function. They leverage technologies such as wearable devices, telemedicine platforms, artificial intelligence and machine learning, mobile health applications, and neuroimaging techniques. These devices are applied in conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and other neurological disorders, serving end users including hospitals and clinics, home care settings, rehabilitation centers, research and academic institutions, and diagnostic laboratories.
The brain disease device and software market consists of revenues earned by entities by providing services such as brain mapping services, remote neurological consultation, neurocognitive assessment, neurofeedback therapy, and personalised rehabilitation planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The brain disease devices and software market also includes sales of brain-computer interface systems, intracranial pressure monitors, transcranial magnetic stimulation devices, virtual reality-based rehabilitation kits, and portable electroencephalography headsets. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Brain Disease Device and Software Market Characteristics
3. Brain Disease Device and Software Market Supply Chain Analysis
4. Global Brain Disease Device and Software Market Trends and Strategies
5. Brain Disease Device and Software Market Analysis of End Use Industries
7. Global Brain Disease Device and Software Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Brain Disease Device and Software Total Addressable Market (TAM) Analysis for the Market
9. Brain Disease Device and Software Market Segmentation
10. Brain Disease Device and Software Market Regional and Country Analysis
11. Asia-Pacific Brain Disease Device and Software Market
12. China Brain Disease Device and Software Market
13. India Brain Disease Device and Software Market
14. Japan Brain Disease Device and Software Market
15. Australia Brain Disease Device and Software Market
16. Indonesia Brain Disease Device and Software Market
17. South Korea Brain Disease Device and Software Market
18. Taiwan Brain Disease Device and Software Market
19. South East Asia Brain Disease Device and Software Market
20. Western Europe Brain Disease Device and Software Market
21. UK Brain Disease Device and Software Market
22. Germany Brain Disease Device and Software Market
23. France Brain Disease Device and Software Market
24. Italy Brain Disease Device and Software Market
25. Spain Brain Disease Device and Software Market
26. Eastern Europe Brain Disease Device and Software Market
27. Russia Brain Disease Device and Software Market
28. North America Brain Disease Device and Software Market
29. USA Brain Disease Device and Software Market
30. Canada Brain Disease Device and Software Market
31. South America Brain Disease Device and Software Market
32. Brazil Brain Disease Device and Software Market
33. Middle East Brain Disease Device and Software Market
34. Africa Brain Disease Device and Software Market
36. Brain Disease Device and Software Market Competitive Landscape and Company Profiles
37. Brain Disease Device and Software Market Other Major and Innovative Companies
40. Brain Disease Device and Software Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Brain Disease Device And Software Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses brain disease device and software market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for brain disease device and software? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The brain disease device and software market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Brain Disease Device; Brain Disease Software2) By Technology: Wearable Technology; Telemedicine Solutions; Artificial Intelligence And Machine Learning; Mobile Health Applications; Neuroimaging Technologies
3) By Application: Alzheimer’s Disease; Parkinson’s Disease; Epilepsy; Other Applications
4) By End-User: Hospitals And Clinics; Home Care Settings; Rehabilitation Centers; Research and Academic Institutions; Diagnostic Laboratories
Subsegments:
1) By Brain Disease Device: Neurostimulation Devices; Brain Imaging Devices; Brain Monitoring Devices; Brain-Computer Interface Devices; Neurorehabilitation Devices2) By Brain Disease Software: Brain Imaging Analysis Software; Cognitive Assessment Software; Neurofeedback Software; Brain Data Management Software; Neurological Disorder Diagnostic Software
Companies Mentioned: Medtronic plc; Insightec Ltd.; Cadwell Industries Inc.; NeuroPace Inc.; Synchron Inc.; Compumedics Ltd.; Neuronetics Inc.; BrainsWay Ltd.; The Magstim Company Ltd.; Paradromics Inc.; Linus Health Inc.; MagVenture A/S; Neurophet Inc.; Neuroelectrics Corporation; BrainScope Company Inc; Blackrock Neurotech LLC; Neurable Inc.; NeuroSigma Inc.; Cognixion Inc.; Brightmind.AI
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Brain Disease Device and Software market report include:- Medtronic plc
- Insightec Ltd.
- Cadwell Industries Inc.
- NeuroPace Inc.
- Synchron Inc.
- Compumedics Ltd.
- Neuronetics Inc.
- BrainsWay Ltd.
- The Magstim Company Ltd.
- Paradromics Inc.
- Linus Health Inc.
- MagVenture A/S
- Neurophet Inc.
- Neuroelectrics Corporation
- BrainScope Company Inc
- Blackrock Neurotech LLC
- Neurable Inc.
- NeuroSigma Inc.
- Cognixion Inc.
- Brightmind.AI
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 17.2 Billion |
| Forecasted Market Value ( USD | $ 25.21 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
